₹1,329.70
+1.72%NSE close, 16 Nov 2026
−16.59%
Eris Lifesciences is a small cap company in the Healthcare sector, listed on NSE under the symbol ERIS. At ₹1,329.70 a share, the market values the whole company at ₹18,427 crore.
In FY26, it reported sales of ₹3,129 crore and a net profit of ₹620 crore, an operating margin of 35.8%. Over the last three years, sales grew 32.4% a year and net profit grew 15.1% a year.
The market values the company at 26.0 times its profit over the last twelve months and 4.45 times its book value; its return on equity is 17.1% and its borrowings are 0.57 times its equity.
Promoters hold 54.74% of the shares, and have pledged 21.3% of their holding. Foreign institutions hold 5.74%, and domestic institutions, mutual funds among them, 20.20%.
Over the past year the share price has fallen 16.1%, and it is 23.6% below its 52-week high.
Companies of a similar size in the same sector include Granules India, Onesource Specialty Pharma, Shilpa Medicare and Caplin Point Laboratories.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Eris Lifesciences | ₹1,329.70 | ₹18,427 cr | 26.0 | 17.1% | +12.60% | −16.13% |
| Granules India | ₹798.95 | ₹19,798 cr | 27.7 | 10.9% | +20.30% | +44.67% |
| Onesource Specialty Pharma | ₹1,612.70 | ₹18,493 cr | n/a | 0.0% | +37.40% | −10.09% |
| Shilpa Medicare | ₹938.35 | ₹18,352 cr | 55.2 | 12.1% | +43.00% | +154.50% |
| Caplin Point Laboratories | ₹2,346.80 | ₹17,838 cr | 25.9 |
Schedule of meet
Notice of Postal Ballot
Schedule of meet
Transcript
Link of Recording
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 486 | 551 | 720 | 739 | 727 | 705 | 773 | 792 | 807 | 757 | 873 | 892 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 311 | 402 | 470 | 477 | 477 | 453 | 496 | 504 | 526 | 483 | 577 | 583 |
| Operating profit | 176 | 148 | 250 | 262 | 250 | 252 | 277 | 288 | 282 | 274 | 296 | 309 |
| Operating margin | 36.1% | 26.9% | 34.7% | 35.5% | 34.4% | 35.8% | 35.8% | 36.4% | 34.9% | 36.2% | 33.9% | 34.7% |
| Other income | 4.2 | 15.2 | 1.6 | 6.8 | 4.2 | 8.0 | 2.7 | 2.8 | 0.0 | 2.2 | 2.4 | 3.2 |
| Interest | 18.1 | 33.0 | 60.4 | 59.5 | 57.2 | 54.3 | 48.7 | 49.6 | 48.8 | 45.6 | 46.7 | 46.4 |
| Depreciation | 45.7 | 53.9 | 75.9 | 80.5 | 81.2 | 77.3 | 70.5 | 69.1 | 70.3 | 69.6 | 72.1 | 73.4 |
| Profit before tax | 116 | 76.7 | 115 | 129 | 116 | 129 | 160 | 172 | 145 | 161 | 180 | 157 |
| Tax | 14.4 | −3.0 | 25.9 | 32.8 | 29.2 | 26.5 | 36.0 | 38.2 | 36.5 | −120 | 36.2 | −31.2 |
| Net profit | 103 | 71.0 | 83.2 | 91.6 | 83.6 | 93.8 | 118 | 120 | 99.7 | 282 | 142 | 184 |
| EPS (₹) | 7.55 | 5.22 | 6.11 | 6.73 | 6.15 | 6.90 | 8.66 | 8.82 | 7.32 | 20.60 | 10.28 | 13.26 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Sales | 982 | 1,074 | 1,212 | 1,347 | 2,009 | 2,894 | 3,129 |
| Expenses | 637 | 706 | 781 | 862 | 1,334 | 1,876 | 2,009 |
| Operating profit | 345 | 368 | 431 | 485 | 675 | 1,017 | 1,120 |
| Operating margin | 35.1% | 34.3% | 35.5% | 36.0% | 33.6% | 35.2% | 35.8% |
| Other income | 31.7 | 15.4 | 8.7 | 26.1 | 23.8 | 18.4 | 7.8 |
| Interest | 22.9 | 2.2 | 1.8 | 4.2 | 84.8 | 231 | 193 |
| Depreciation | 36.4 | 50.3 | 43.0 | 64.7 | 183 | 315 | 280 |
| Profit before tax | 317 | 331 | 395 | 442 | 431 | 489 | 638 |
| Tax | 26.2 | 34.8 | 39.4 | 36.4 | 34.2 | 114 | −9.0 |
| Net profit | 291 | 297 | 355 | 406 | 392 | 352 | 620 |
| EPS (₹) | 21.15 | 21.61 | 26.16 | 29.89 | 28.82 | 25.85 | 45.33 |
₹ crore, at each year's end and the latest half year.
| Line | FY23 | FY24 | FY25 | FY26 | Sep 2026 |
|---|---|---|---|---|---|
| Shareholders’ equity | 2,196 | 2,586 | 2,854 | 3,903 | 4,144 |
| Borrowings | 830 | 2,735 | 2,478 | 2,310 | 2,382 |
| Total liabilities | 1,447 | 3,827 | 3,761 | 3,470 | 3,440 |
| Fixed assets | 356 | 505 | 662 | 708 | 716 |
| Investments | 6.7 | 15.5 | 10.5 | 10.0 | 10.0 |
| Cash and equivalents | 56.0 | 94.3 | 200 | 54.7 | 238 |
| Total assets | 3,667 | 7,049 | 7,033 | 7,366 | 7,581 |
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 378 | 1,065 | 538 | 637 |
| From investing | −320 | −80.0 | −369 | −285 |
| From financing | −44.7 | −881 | −314 | −169 |
| Spent on fixed assets | −121 | −155 | −297 | −220 |
| Free cash flow | 257 | 910 | 241 | 417 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Net margin | 29.6% | 27.6% | 29.3% | 30.1% | 19.5% | 12.2% | 19.8% |
| Operating margin | 35.1% | 34.3% | 35.5% | 36.0% | 33.6% | 35.2% | 35.8% |
| Return on equity | – | – | – | – | 15.2% | 12.3% | 15.9% |
| Return on capital employed | – | – | – | – | 9.7% | 13.5% | 13.4% |
| Return on assets | – | – | – | – | 5.6% | 5.0% | 8.4% |
| Debt to equity | – | – | – | – | 1.06 | 0.87 | 0.59 |
| Interest coverage | 14.90 | 154.40 | 220.20 | 107.60 | 6.10 | 3.10 | 4.30 |
| Debt to assets | – | – | – | – | 0.39 | 0.35 | 0.31 |
| Current ratio | – | – | – | – | 0.91 | 0.91 | 0.74 |
| Quick ratio | – | – | – | – | 0.83 | 0.67 | 0.53 |
| Cash ratio | – | – | – | – | 0.04 | 0.14 | 0.03 |
| Asset turnover | – | – | – | – | 0.29 | 0.41 | 0.42 |
| Fixed asset turnover | – | – | – | – | 3.98 | 4.37 | 4.42 |
| Inventory turnover | – | – | – | – | 2.00 | 2.10 | 1.80 |
| Receivables turnover | – | – | – | – | 4.80 | 6.30 | 4.60 |
| Gross margin | – | – | – | – | 81.1% | 75.3% | 74.6% |
| Cash from operations to profit | – | – | – | 93.0% | – | 303.0% | 87.0% |
| Effective tax rate | 8.3% | 10.5% | 10.0% | 8.2% | 7.9% | 23.4% | – |
| 17.7% |
| +17.90% |
| +17.08% |
| Syngene International | ₹441.20 | ₹17,810 cr | 95.7 | 3.8% | −8.60% | −28.91% |
|---|
| Cohance Lifesciences | ₹457.60 | ₹17,508 cr | 369.6 | 1.2% | −14.20% | −36.78% |
|---|
| Pfizer | ₹3,818.30 | ₹17,468 cr | 20.3 | 19.6% | +13.20% | −24.65% |
|---|
| Poly Medicure | ₹1,684.30 | ₹17,072 cr | 53.6 | 9.8% | +30.80% | −11.21% |
|---|
The financial results for the period ended September 30, 2026.
Resignation of Mr Krishnakumar vaidyanathan as Executive Director of the company w.e.f. close of September 30, 2026.
A copy Srutinizers report of Annual General Meeting held on September 25, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 25, 2026
Allotment of 155264 securities pursuant to ESOP/ESPS at its meeting held on September 22, 2026
Appointment of Mr as Non- Executive Independent Director of the company w.e.f. September 26, 2026.
Resignation of Mr Krishnakumar Vaidyanathan as Executive Director of the company w.e.f. September 30, 2026.
Loan Agreement